Alto Neuroscience Reports Topline Data from Phase 2 Proof-of-Concept Study of ALTO-101 and Highlights Pipeline Advancements

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/12/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. CRM
9. MSFT
10. DOL:CN

Go back to Alto Neuroscience Reports Topline Data from Phase 2 Proof-of-Concept Study of ALTO-101 and Highlights Pipeline Advancements
(NYSE: ANRO) Delayed: 21.47 +0.04 (0.19%)
Previous Close $21.43    52 Week High $ 
Open $21.50    52 Week Low $ 
Day High $22.79    P/E N/A 
Day Low $21.24    EPS $ 
Volume 272,048